Table 2.
Outcomes in Derivation and Validation Cohorts
| Variable | Derivation (n=509) |
Validation (n=278) |
|---|---|---|
| Decompensation (0-5 yrs) | 7.27% (37/509) | 7.55% (21/278) |
| • Ascites | 5.70% (29/509) | 6.47% (18/278) |
| • Variceal Hemorrhage | 1.38% (7/509) | 0.72% (2/278) |
| • Hepatic Encephalopathy | 0.20% (1/509) | 0.36% (1/278) |
| Censoring Events (0-5 yrs) | 92.73% (472/509) | 92.44% (257/278) |
| • Liver transplantationa | 3.73% (19/509) | 11.51% (32/278) |
| • Confirmed CCA | 4.51% (23/509) | 2.51% (7/278) |
| • Last Clinical Encounter | 84.50% (430/509) | 78.42% (218/278) |
| Decompensation (2-7 yrs)b | 7.93% (13/164) | 5.10% (5/98) |
| • Ascites | 4.27% (7/164) | 3.03% (3/99) |
| • Variceal Hemorrhage | 3.04% (5/164) | 1.01% (1/99) |
| • Hepatic Encephalopathy | 0.61% (1/164) | 1.01% (1/99) |
| Censoring Events (2-7 yrs) | 92.07% (151/164) | 94.90% (93/98) |
| • Liver transplantationc | 5.49% (9/164) | 8.16% (8/98) |
| • Confirmed CCA | 3.05% (5/164) | 1.02% (1/98) |
| • Last Clinical Encounter | 83.54% (137/164) | 85.71% (84/98) |
Abbreviations: PSC (primary sclerosing cholangitis); CCA (cholangiocarcinoma).
Events that developed first are shown.
Derivation transplant indications (PSC symptoms not associated with portal hypertension n=18; concern for biliary neoplasia n=1); Validation transplant indications (PSC symptoms not associated with portal hypertension n=29; concern for biliary neoplasia n=3).
After re-applying our inclusion/exclusion criteria at year 2, the derivation cohort included 164 subjects & validation cohort included 98 subjects.
Derivation transplant indications (PSC symptoms not associated with portal hypertension n=9); Validation transplant indications (PSC symptoms not associated with portal hypertension n=8).